Ethnopharmacological Approaches for Therapy of Jaundice: Part II. Highly Used Plant Species from Acanthaceae, Euphorbiaceae, Asteraceae, Combretaceae, and Fabaceae Families

Devesh Tewari1†, Andrei Mocan2,3†, Emil D. Parvanov4, Archana N. Sah1, Seyed M. Nabavi5, Lukasz Huminiecki6, Zheng Fei Ma7,8, Yeong Yeh Lee7, Jarosław O. Horbańczuk6 and Atanas G. Atanasov6,8,9,10∗

1 Department of Pharmaceutical Sciences, Faculty of Technology, Kumaun University, Nainital, India, 2 Department of Pharmaceutical Botany, “Iuliu Hașieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, 3 ICHAT and Institute for Life Sciences, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania, 4 Division BIOCEV, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czechia, 5 Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran, 6 Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, Jastrzebiec, Poland, 7 School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia, 8 Department of Public Health, Xi’an Jiaotong-Liverpool University, Suzhou, China, 9 Department of Pharmacognosy, University of Vienna, Vienna, Austria, 10 Department of Vascular Biology and Thrombosis Research, Centre for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria

In many developing countries, jaundice is the common symptom of hepatic diseases which are a major cause of mortality. The use of natural product-based therapies is very popular for such hepatic disorders. A great number of medicinal plants have been utilized for this purpose and some facilitated the discovery of active compounds which helped the development of new synthetic drugs against jaundice. However, more epidemiological studies and clinical trials are required for the practical implementation of the plant pharmacotherapy of jaundice. The focus of this second part of our review is on several of the most prominent plants used against jaundice identified in the analysis performed in the first part of the review viz. Andrographis paniculata (Burm.f.) Nees, Silybum marianum (L.) Gaertn., Terminalia chebula Retz., Glycyrrhiza glabra L. and some species of genus Phyllanthus. Furthermore, we discuss their physiological effects, biologically active ingredients, and the potential mechanisms of action. Some of the most important active ingredients were silybin (also recommended by German commission), phyllanthin and andrographolide, whose action leads to bilirubin reduction and normalization of the levels of relevant serum enzymes indicative for the pathophysiological status of the liver.

Keywords: jaundice, bilirubin, oxidative stress, traditional use, phytoconstituents, serum enzymes, alkaline phosphatase
THE MEDICINAL PLANTS OF PRIME IMPORTANCE FOR THE TREATMENT OF JAUNDICE

In the first part of the review, we presented an overview of the history, symptoms and causes of jaundice and the significance and diversity of medicinal plants used in its treatment. We also presented an exhaustive list of 207 plant species from 20 countries used for the treatment of jaundice. These plants were mainly indicated by different ethnopharmacological or ethnobotanical surveys. Based on their most popular use, several of the 207 plants classified in five different families are described in the current review based on their therapeutic profiles with special reference to jaundice and hepato-protective mechanism (Figure 1).

Andrographis paniculata (Burm.f.) Nees

Andrographis paniculata (Burm.f.) Nees is a medicinal plant which belongs to the family Acanthaceae. The major biologically active chemical constituents of the plant are diterpene lactones, either free, or glycosidated. These include andrographolide, deoxyandrographolide, neoandrographolide, andrographiside, andrographanoside, etc. (Figure 2) (Xu, 1986; Thai Pharmacopoeia Committee, 1995; WHO, 1999). It is used as a cure for a broad spectrum of diseases and utilized traditionally for centuries in folk medicine, mainly in Asia (Jarukamjorn et al., 2006). Aerial parts of A. paniculata are included in traditional remedies, and are being used for a broad range of disorders, more specifically as hepatic stimulant and hepato-protective agent along with other liver disorders and jaundice (Kapil et al., 1993; Trivedi and Rawal, 2000). The medicinal effect of the aerial parts of the plant is represented by their in vitro and in vivo anti-hepatotoxic activities (Gupta et al., 1990; Chander et al., 1995). These studies demonstrated marked effect of the A. paniculata and its diterpenes andrographolide and neoandrographolide on the alkaline phosphatase (ALP), serum lipoprotein-X, GPT, GOT, bilirubin and also the effect of A. paniculata on the enterotoxin in animal models. These studies also showed promising protective effects of the diterpenes andrographolide and neoandrographolide in hepatic damage. However, further clinical studies with sufficient number of subjects are required to further prove the efficacy of these compounds in humans.

Various studies have been carried out to explore the therapeutic effect of this plant, particularly its antiviral (Calabrese et al., 2000), anti-inflammatory (Shen et al., 2002), immune stimulatory (Puri et al., 1993; Iruretagoyena et al., 2004), and anti-cancer effects (Kumar et al., 2004). A. paniculata extract, and in particular its active compound andrographolide and its related analogs were shown to exhibit effects on various hepatic enzymes like N-and O-demethylase, aniline hydroxylase (Choudhury and Poddar, 1984), AspAT, alanine aminotransferase (ALT) (Trivedi and Rawal, 2000), DT-diaphorase (DTD) and glutathione S-transferase (GST) (Singh et al., 2001). The aqueous extract of A. paniculata significantly increased the pentoxyresorufin O-dealkylase (PROD) activity, suggesting that A. paniculata constituents might affect hepatic cytochrome P-450 enzyme (Jarukamjorn et al., 2006).

CCL4 induced hepatotoxicity in mice was reduced by methanol extract of A. paniculata and the histopathological liver changes were reversed (Handa and Sharma, 1990), as well as the elevated concentrations of different enzymes like SGOT; bilirubin and hepatic triglycerides were reduced by andrographolide (Handa and Sharma, 1990; Sharma et al., 1991). Andrographolide also exerted a prominent protective effect against hepatotoxicity caused by various substances viz. D-Gal N (Saraswat et al., 1995), ethanol (Pramyothin et al., 1994), paracetamol (Visen et al., 1993), and CCl4 (Kapil et al., 1993). Comparison showed that andrographolide exhibits higher efficiency than the standard hepatoprotective agent silymarin (Kapil et al., 1993; Visen et al., 1993).

However, it is still not clear if the extract, or the pure substance has higher efficiency based on their inhibition on CCl4 and paracetamol toxicity (Choudhury and Poddar, 1984; Visen et al., 1993). This can be due to presence of several complex phytochemicals in the extract, which can lead to synergistic, or antagonistic effects during bioactivation and detoxification (Singh et al., 2001).

A report on modulation potential of phases I and II enzymes and antioxidative enzymes by A. paniculata revealed a remarkable effect on hepatic metabolic enzymes. The activities of DTD and GST were increased in mouse liver and other organs by an 80% hydroalcoholic extract of the plant and thus strengthening the xenobiotic metabolism toward detoxification, which plays an important role in chemoprevention and cytoprotection (Singh et al., 2001). The effect of the plant was also correlated with their therapeutic profiles with special reference to jaundice and hepato-protective mechanism (Figure 1).

Abbreviations: ACE, angiotensin converting enzyme; Ach, acetylcholine; ALP, alkaline phosphatase; ALT, alanine transaminase; AR, aldose reductase; AspAT, aspartate aminotransferase; AST, aspartate transaminase; ATP, adenosine triphosphate; AUC, area under the concentration time curve; CAMP, cyclic adenosine monophosphate; CaOX, calcium oxalate; CCL4, carbon tetrachloride; CED, Caenorhabditis elegans cell-death gene; CGT, ceramide galactosyltransferase; Cmax, maximum plasma concentration; COX, cyclooxygenase; CrMP, chromium mesoporphyrin; CYP, cytochromes P450; CYP2E1, Cytochrome P450 2E1; D-Gal N, D-galactosamine; DTD, DT-diaphorase; ERK, extracellular signal-regulated kinase; ET-NANB, enteric transmitted non-A non-B; GABA, gamma-Aminobutyric acid (g-Aminobutyric acid); GOT, glutamic oxaloacetic transaminase; GSH, glutathione stimulation hormone; GST, glutathione S-transferase; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus/hepatitis delta virus; HEV, hepatitis E virus; HIV, human immunodeficiency virus; HO 1, heme oxygenase 1; ICE, interleukin-1beta-converting enzyme; INH, isoniazid; JNK, c-Jun N-terminal kinases; LDH, lactate dehydrogenase; LOX, lipoxygense; LPS, Lipopolysaccharide; LR, renal clearance; MAPK, mitogen-activated protein kinases; MDA, malondialdehyde; mRNA, messenger RNA; NA, noradrenaline; Na+ K+ ATPase, sodium potassium adenosine triphosphatase; NANBH, non-A, non-B hepatitis; NK1, neurokinin 1; OTC; over the counter; PROD, pentoxysresorufin O-dealkylase; PZA, pyrazinamide; RBC, red blood cells; RIF, rifampin; ROS, reactive oxygen species; RT, reverse transcriptase; SGOT, serum glutamic oxaloacetic transaminase; SmP, tin mesoporphyrin; SOID, superoxide dismutases; t1/2, elimination half life; t-BHP, tert-butyl hydroperoxide; TCM, Traditional Chinese medicine; TK, tyrosine kinase; I50, maximum time; TNF-α, tumor necrosis factor-α; UDPGT, uridine diphosphoglucuronyl transferase; UGT, uridine 5’-diphospho-glucuronosyltransferase (UDPG- glucuronosyltransferase); wh. pl., whole plant; WHO, World Health Organization; WW II, World War II.
In a clinical study by Churvedi et al. (1983) outstanding results by using *A. paniculata* for the treatment of infectious hepatitis were achieved. Improvements in appetite, jaundice, fever and epigastric discomfort were observed in all patients within 4 weeks. A significant reduction in serum bilirubin level (up to 10-fold) was recorded as well. Apart from this, ALP, SGPT and SGOT, were also significantly improved, suggesting that *A. paniculata* might be considered as the cheapest and the most beneficial cure for infectious hepatitis (Churvedi et al., 1983). Although these results appear promising, it should be considered that this study conducted more than three decades ago had low number of studied subjects. The lack of statistical power and the insufficient data by the former experiments require the conduction of larger clinical trials to elucidate the effects of the active compounds. It should be considered that next to the major constituents andrographolide and andrographin there may be also other compounds modulating the bioactivities of the plant. Therefore, further studies on the synergistic and antagonistic effects of the plant compounds combined with knowledge about their deeper molecular mechanisms are required to unravel the mode of action of *A. paniculata*.

In brief, *A. paniculata* seems effective in various liver diseases such as viral and toxic hepatitis and intra and extra hepatic cholestasis, that would reduce jaundice (Deng et al., 1982; Handa and Sharma, 1990; Visen et al., 1993). However, there are also reports about its compounds cytotoxicity (Nanduri et al., 2004) and toxicity for the male reproductive system (Akbarsha and Murugaian, 2000). Therefore, further clinical studies are required to establish the safety and clinical efficacy of the long term use.

**GENUS Phyllanthus**

The genus *Phyllanthus* belongs to the Euphorbiaceae family and is widely distributed throughout the tropical and subtropical zones being described for the first time in 1773 by Linnaeus. The genus comprises of about 550–1200 species (Unander et al., 1990, 1991, 1992, 1995; Mabberley, 2008; Cruz-Vega et al., 2009). A number of species of this genus have been used since ancient
times to treat a broad spectrum of diseases such as the hepatitis B virus (HBV) infection, bone disorders (Piva et al., 2009), diabetes (Kusirisin et al., 2009), intestinal infections and disturbance of the kidney and urinary bladder (Morton, 1981; Oliver-Bever, 1983; Unander et al., 1990, 1991, 1992, 1995; Calixto et al., 1998; Cruz-Vega et al., 2009). Evidences for utilization of this genus are present in the aboriginal texts of Ayurveda (also known as “Ancient Science of Life”), which is one of the ancient traditional medicine systems of the world, native to India for more than 2000 years. Apart from India, these species are also used in other locations viz. Central and South America, Philippines, Guam, Nigeria, Cuba, China, and Africa (Thyagarajan et al., 1988).

A variety of bioactive molecules have been isolated and characterized from a large number of species of this genus (Figure 3). Phytochemical studies revealed the presence of lignans, alkaloids, tannins, lactones, and flavonoids (Pettit et al., 1982a,b; Foo and Wong, 1992; Bachmann et al., 1993; Foo, 1995; Filho et al., 1996; Calixto et al., 1998). Therapeutic activities have been reported from phytoestrogens like β-sitosterol, stigmasterols, and campesterol, present in Phyllanthus species having anticonvulsant action among other effects. Furthermore, rutin in Phyllanthus emblica, P. niruri, and P. amarus is associated with analgesic and anti-inflammatory activity (Alcaraz and Jiménez, 1988; Pathak et al., 1991; Santos et al., 1994); ellagic acid found in P. emblica and P. niruri acts as an aldose reductase inhibitor (Shimizu et al., 1989; Unander et al., 1991); geraniin has antiinflammatory, analgesic and ACE-inhibitor activity; and quercetin has mitochondrial ATPase, phosphorylase and tyrosines kinase inhibition, analgesic activity, cyclooxygenase (COX) inhibition; phospholipase A-2 inhibition and tyrosine kinase inhibition, antiinflammatory activity, cyclooxygenase (COX) inhibition; phospholipase A-2 inhibition and mutagenic effect on bacteria (Suolinna et al., 1974; Beretz et al., 1978; Shisheva and Shechter, 1992; Duarte et al., 1993; Lindahl and Tagesson, 1993; Morales and Lozoya, 1994; Filho et al., 1996; Qian-Cutrone et al., 1996; Calixto et al., 1998; Ullah et al., 2013). Niruriside present in P. niruri has HIV transcriptase inhibitory activity (Hussain et al., 1995, 1997; Cruz et al., 1998; Sanchez de Medina et al., 2002); gallocatechin, isolated by tissue culture of P. niruri (Ishimaru et al., 1992) and catechins in general have suppressive effect on the growth of hepatic and colon epithelial cancer cell lines (Usato et al., 2001). Moreover, the flavone glycoside nirurin [5,6,7,4-tetrahydroxy-8-(3-methylbut-2-enyl)] and some volatile constituents were also reported as present in the plant (Bagalkotkar et al., 2006). P. niruri gained particular attention globally due to its anti HBV activity during late 1980s (Venkateswaran et al., 1987).

The extract of P. amarus Schumach. & Thonn. demonstrated steady inhibition on the HBV surface antigen in vitro. Most of the plant extracts of this genus are capable of acting as reverse transcriptase inhibitors and DNA polymerase inhibitors and, thus, preventing the replication of HBV (Thyagarajan et al., 1988; Unander and Blumberg, 1991; Ogata et al., 1992; Unander et al., 1995; Lee et al., 1996; Calixto et al., 1998; Padmalatha et al., 2009). The chemical constituents responsible for HBV suppression are still not well known, although ellagic acid may have a role for this effect. Further reports showed that hydrolysable fraction from P. amarus acts via inhibition of cAMP dependent protein kinase catalytic subunit (Polya et al., 1995). Clinical studies revealed that P. amarus extract had very little, or no adverse effect on the patients (Thyagarajan et al., 1988; Wang et al., 2005).
The toxic and therapeutic effects of other plants of this genus like *P. urinaria* L. and *P. niruri* were examined in 123 patients and significant improvements were observed in those with chronic hepatitis (Wang et al., 2005). In a study performed by Yeh et al. (1993), a reversible inhibition of cellular proliferation and suppression of HBV surface antigen was observed in human hepatoma cell lines (HepA2). The biological effect of *P. amarus* extract and its medical use in jaundice treatment was explained by reducing the mRNA level of the HBV surface antigen (Wang et al., 2005). The HBV suppression by plant extracts of *Phyllanthus* origin is a well-known fact. However, the discovery of active molecules and their mechanism of action is a matter of future studies. This will allow improving liver function and resolving jaundice by their more efficient analogs, or by combination with other compounds. In addition to the spectrum of favorable activities of this genus, the clastogenic effect of nickel chloride on mouse bone marrow cells is antagonized by *P. emblica* and *P. niruri* extracts (Agarwal et al., 1992); and potential hypoglycemic, diuretic and hypotensive effects of *P. amarus* were also observed in a human clinical study (Srividya and Periwal, 1995). The hepatoprotective activity of different *Phyllanthus* species was also evaluated in animal models (Syamasundar et al., 1985; Dhir et al., 1990; Gulati et al., 1995; Prakash et al., 1995). Liver injury induced by CCl₄ was counteracted by *P. niruri* and *P. urinaria*, but not by *P. simplex*, and normalization of the elevated serum levels of transaminases (SGOT and GPT) in rat liver was observed (Syamasundar et al., 1985; Prakash et al., 1995); quercetin, which is one of the main component of *P. emblica*, exhibited hepatoprotective effect after paracetamol and country-made liquor intake in mice, and *P. niruri* also led to similar result (Umarani et al., 1985; Gulati et al., 1995; Unander et al., 1995). It is assumed that most of the phytoconstituents present in this genus, as described earlier, interact with key regulatory enzymes viz. COX, LOX, AR, ACE, phospholipase A-2, tyrosine kinase (TK), reverse transcriptase (RT) mitochondrial ATPase and phosphodiesterases (Calixto et al., 1998). The clinical study of Thyagarajan et al. (1988) found weaker responses to HBV treatment by *P. amarus* extracts in males vs. females, however, the number of individuals was insufficient for statistical significance of this difference.

In conclusion, it is evident that the plants of genus *Phyllanthus* have a great potential as therapeutics against jaundice. However,
there is a need of proper clinical trials aimed toward the establishment of safety and efficacy of the genus Phyllanthus species in a standardized way.

**Silybum marianum (L.) Gaertn. (milk thistle)**

*Silybum marianum* (L.) Gaertn. (*Carduus marianus* L.), belonging to the family Asteraceae, or Compositae, has been used for more than 2000 years, in particular as a remedy for hepatobiliary disorders since 16th century (Flora et al., 1998; Schuppan et al., 1999). The plant is commonly known as the milk thistle, Our lady's thistle and St. Mary's thistle (Schuppan et al., 1999; Wellington and Jarvis, 2001). One of the most important hepatoprotective agent, silymarin is obtained from milk thistle fruits and seeds. The plant extract has a variety of phytoconstituents including silybin, or sometimes incorrectly called silibinin, which are flavonolignans, as well as isosilibin, silychristin, and silidianin (Figure 4). The plant is widely spread in the United States and it became officially used in clinical practice after 1969 (Morazzone and Bombardelli, 1995; Flora et al., 1998; Simanek et al., 2000).

A study by Flora et al. (1996) revealed that 31% of patients were taking OTC milk thistle as an alternative agent for liver diseases. Dioscorides, the famous Greek herbalist, wrote about the use of tea from milk thistle seed against snake poison/bite (Greive, 1981). The use of milk thistle against hyperbilirubinemia was described by Pliny The Elder (AD 23–79) (Foster, 1991). Later, in 1596, Gerarde considered milk thistle as the best remedy against black bile or melancholy (Hobbs, 1987). Furthermore, in 1787 the seeds and the roots of the plant were noted as an excellent remedy to treat liver and spleen obstruction and to cure jaundice along with expelling stones (Greive, 1981).

General features of flavonoids are their membrane stabilizing effect and free radical capture, which defines their biological activity. Silybin, being a flavonolignan is considered as the most efficient phytochemical responsible for different therapeutic activities of the plant viz. hepatoprotective, antiangiogenic, chemopreventive etc. (Gazak et al., 2007). Fruits and seeds are considered to be the richest in active constituents along with leaves (Harnisch and Stölze, 1983; Hobbs, 1987; Flora et al., 1998). Silybin is the major component of silymarin, constituting about 50–70% of the silymarin extract (Loguercio and Festi, 2011). The effect of silymarin against liver diseases of different etiology such as hepatobiliary diseases was reported during 1960s (Wagner et al., 1974; Luper, 1998; Pradhan and Girish, 2006). Silymarin has been extensively studied for its different pharmacokinetic and pharmacodynamic properties, and mechanism of liver protective action (Ramellini and Meldolesi, 1974; Miadonna et al., 1987; Feher et al., 1989; Barzaghi et al., 1990; Wellington and Jarvis, 2001).

Moreover, the effect of silymarin on liver cirrhosis was investigated in several randomized double blind clinical studies (Salmi and Sarna, 1982; Feher et al., 1989; Ferenci et al., 1989; Bounout et al., 1992; Parés et al., 1998). Some studies revealed a significant increase in the patient survival rate after the treatment with silymarin (Ferenci et al., 1989; Parés et al., 1998). It was also reported that slightly elevated levels of serum bilirubin are normalized by silymarin treatment and CGT, ALT, and AST are decreased significantly (Feher et al., 1989). However, another study showed that 420 mg/day dose of silymarin did not inflict significant effect on the serum level of total bilirubin, ALP and, AST, in patients with primary biliary cirrhosis (Angulo et al., 2000). The opposite result was obtained at the same dose, i.e., 420 mg/day, in a randomized, multicentric, double blind study with larger number of patients (n = 59). Significant reduction of serum AST and bilirubin was recorded as comparable to placebo in patients with acute viral hepatitis A or B (Magliulo et al., 1978). Serum ALT level was decreased significantly in patients with chronic hepatitis by studies including 180 patients with chronic persistent hepatitis (Tănăsescu et al., 1987).

The daily dose of 12–15 g of crude herb, or 200–400 mg of silymarin (counted as silybin) is recommended by German commission E (Meyer et al., 1999). Tablets, or capsules with a dose of 70 or 140 mg, or milk thistle fruit infusion are also used (Fleming, 1998; Meyer et al., 1999; Wellington and Jarvis, 2001). The drug should be avoided for children below age of 12 years due to lack of proper clinical tests for its effect. Several other parameters like enhancement of SOD activity, as well as SOD expression in erythrocytes and lymphocytes along with the increase of glutathione and glutathione peroxidase levels are also associated with silymarin intake (Wellington and Jarvis, 2001). Consequently, silymarin is becoming a more popular OTC herbal preparation in Europe due to its liver regeneration properties. A large number of patients with different liver disease are taking this drug with other prescribed medications in United States as well (Leng-Peschlow, 1994; Morazzone and Bombardelli, 1995; Schuppan et al., 1999; Simanek et al., 2000; Wellington and Jarvis, 2001).

**Terminalia chebula Retz.**

*Terminalia chebula* Retz. originates from India (Choi et al., 2015) and belongs to the family Combretaceae commonly known as “chebulic myrobalan” and “Haritaki” (Tasdug et al., 2006; Yeasmin et al., 2016). *T. chebula* contains significant amount of phenolic and flavonoid compounds. Some of the main constituents are 2,4-chebulyl-β-D-glucopyranose, ellagic acid, gallic acid and chebulic ellagittannins (Figure 5) (Juang et al., 2004; Panunto et al., 2010; Li et al., 2014).

The plant is well recognized for its various medicinal uses, and it is one of the main ingredient of the important Ayurvedic formulation “Triphala” (three myrobalan fruits) (Anand et al., 1994). Ayurvedic Pharmacopoeia of India prescribes this formulation to cure kidney and liver dysfunctions (Chatterjee and Pakrashi, 1991; Mhaskar et al., 2000). The use of dried ripe fruit of *T. chebula* is reported in Ayurveda as antitussive, cardiotonic, homeostatic, diuretic and laxative (Lee H.-S. et al., 2005; Sarkar et al., 2012). There are several formulations with *T. chebula* as the main ingredient, for example the official formulation in Ayurvedic Pharmacopoeia of India named “Triphala Ghrita”, which is a mixture of *T. chebula*, *T. bellirica*, "
**FIGURE 4** | The chemical structures of phytoconstituents of Milk thistle (A) Silybin and (B) isosilibin.

**FIGURE 5** | The chemical structures of phytoconstituents of Terminalia chebula (A) Ellagic acid and (B) Gallic acid.

*Phyllanthus emblica* and 19 other compounds found to have beneficial effect on jaundice (*Kamala*). The plant is also the main ingredient of the polyherbal hepatoprotective drug HP-1 (Tasduq et al., 2003).

Together with the suppressive effect on hepatic fibrosis, the fruit extract of *T. chebula* inhibits the lipid peroxidase and affects the iron chelation associated protein oxidation. Reduction in ALT, AST, ALP and total bilirubin level indicates protection of liver damage (Sharma and Rathore, 2010; Sarkar et al., 2012; Yeasmin et al., 2016). The antioxidative role of the 70 % methanolic extract is due to its chelating properties for iron ion and thus decreasing the toxicity in iron overload states (Harrison, 1977; Sarkar et al., 2012). Aqueous fruit extract of *T. chebula* was tested against severe acute liver injury by t-BHP (tert-butyldihydroperoxide) in mice (Choi et al., 2015). The t-BHP causes rigorous necrosis, damage of hepatic tissues and significant elevations of serum enzymes like LDH, AST, and ALT. *T. chebula* fruit extract normalizes the liver enzyme levels and exhibits antioxidant effects overall providing liver protection (Owoyele et al., 2001; Fu et al., 2010; Choi et al., 2015; Yeasmin et al., 2016).

*T. chebula* extract also normalizes the abnormal level of CYP2E1 gene expression, which is mainly activated during drug metabolism process (Rush et al., 1985; Choi et al., 2015). Altogether with the hepatoprotective effect in different models (Tasduq et al., 2006; Sarkar et al., 2012), the immune modulatory action mediated by chebulagic acid in *T. chebula* is also reported (Lee S. et al., 2005). Additionally, due to its antioxidant activity and bilirubin level lowering effect *T. chebula* extract ensures hepatoprotection against paracetamol-induced damage. The reduction in serum bilirubin level is the most important evidence supporting the traditional use of the plant against jaundice.

Hepatotoxicity associated with prolonged use of rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA), which are used in a combination for the chemoprophylaxis and treatment of tuberculosis (Wong et al., 2000), is common. The side effects of anti-tuberculosis drugs on liver were reduced after the use of *T. chebula* fruit extract containing 0.250% chebuloside on an oral administration for 12 weeks in rats (Tasduq et al., 2006). Membranes (cytoplasmic and microsomal) were found as the main target of action for *T. chebula* extract. Hepatoprotective effect of *T. chebula* is also based on effects on the Na$^+$, K$^+$ - ATPase and CYP2E1, similarly to silymarin (Mourelle et al., 1989; Tasduq et al., 2006).

**Glycyrrhiza glabra** L.

Genus *Glycyrrhiza* belongs to the family Fabaceae, and consists of around 30 species. The plants of this genus are perennial herbs and are native to Mediterranean region and Asia, from Iran to Southern Russia. They are also cultivated throughout Europe and Asia (Blumenthal et al., 2000; Asl and Hosseinazadeh, 2008). The most common plant of this genus is *Glycyrrhiza glabra* L. also known as licorice. It has been utilized for relief of catarrh of the respiratory organs since ancient Egyptian times and described in the Ebers papyrus (1552 B.C.) and Codex Hammurabi (2100 B.C.). It also appears in "De Materia Medica" of Dioscorides (40–90 A.D.) in Rome and "De Causis Plantarum" and "De
Historia Plantarum” of Theophrastus (371–286 B.C.) in Greece. According to Dioscorides manuscript entitled “Glukoriza” (sweet root), the expressed sap of its root is used for the liver, stomach, and kidney related ailments (Shibata, 2000). Flavonoid content from the root was found to exert antiulcerogenic and spasmyolytic activity (Kitagawa et al., 1994; Fukai et al., 1996; Evans, 2009). Several isoflavonoid derivatives such as shinpterocarpin, glabrone, glabrene, glabridin, lico-isoflavones A and B etc. are also present in licorice (Williamson, 2003; Asl and Hosseinzadeh, 2008). The ancient medicinal use of licorice has been documented in the Chinese medical book “Shang-Han-Za-Bing-Lun” as well. Among 113 prescriptions of Shang-Han-Lun, 80% contain licorice as a significant constituent (Shibata, 2000). The cultivation of this plant in England has been traced back to the sixteenth century (Evans, 2009). The plant is utilized for its medicinal activity since 500 BC and described as ‘the grandfather of the herbs’ (Ody, 2000). It is known under different names like licorice, gancao, yashi-madhu, kanzoh and sweet root (Blumenthal et al., 2000; Nomura et al., 2002; Asl and Hosseinzadeh, 2008). G. glabra L., G. bucharica Regel, G. foetida Desf., G. aspera Pall., G. echinata L., and G. inflata Batalin are some of the species of this genus among which three have varieties: G. glabra viz. G. glabra var typica (Spanish and Italian licorice), G. glabra var glandulifera (Russian licorice) and G. glabra var violacea (Turkish licorice) (Nomura et al., 2002). Substantial research has been carried out for the main medicinal effects of licorice since 1990 largely by the Japanese scientists, since the drug is widely used in the traditional medicine of Japan, brought earlier from China (Wang et al., 1996; Arase et al., 1997; Shibata, 2000; van Rossum et al., 2001; Hidaka et al., 2007; Evans, 2009; Eerdunbayaer et al., 2014; Ohno et al., 2014).

The sweet taste of licorice is due to the triterpenoid saponin known as glycyrrhizin (glycyrrhizic acid) (Figure 6). Further, the glycyrrhizinic acid is diglucopyranosiduronic acid of the glycyrrhetinic acid, which has a triterpenoid structure (Kokate et al., 2003; Evans, 2009). Flavonoids are the cause of the yellow color of licorice, and they were recognized in 1978 for their inhibitory effect on gastric acid secretion (Dastagir and Rizvi, 2016). Flavonoids include liquiritin, isoliquiritin, liquiritigenin, neoliquiritin, rhamnoliquiritin and others (Williamson, 2003; Asl and Hosseinzadeh, 2008).

The leaves, roots and rhizomes of licorice have been used traditionally for different purposes including wound healing (Dafni et al., 1984), cough (Fujita et al., 1995) cystitis (Yarnell, 1997), tuberculosis (Arseculeratne et al., 1985), gastric ulcer (Varshney et al., 1983) and diabetes (Rajurkar and Pardeshi, 1997). Licorice shows different pharmacological activities such as hepatoprotective (Nakamura et al., 1985; Lin and Tome, 1988; Nose et al., 1994; Lin et al., 1999; Al-Qarawi et al., 2001; Jeong et al., 2002; Lee et al., 2009; Huo et al., 2011), anti-inflammatory (Finney and Somers, 1958; Ohuchi and Tsurufuji, 1982; Yu et al., 2015; Yang et al., 2016), antiviral, antimicrobial (Shebl et al., 2012; Sabouri Ghannad et al., 2014; Wang et al., 2015) and immunomodulatory effect (Kimura et al., 1992; Tandon et al., 2002; Raphael and Kuttan, 2003). Glycyrrhizin is widely used for treatment of different types of hepatitis (Yamamoto et al., 1958; Suzuki et al., 1977). However, there are reports of aldosteronism effect when used in enormous doses (Ullmann et al., 1975; Epstein et al., 1977; Ishikawa and Saito, 1980). Pharmacokinetic studies of glycyrrhizin were also carried out in patients with hepatitis and liver cirrhosis and a monophasic decline in plasma concentration of glycyrrhizin was found with 6.0 h elimination half-life ($t_{1/2}$) and 7.9 ml h$^{-1}$ kg$^{-1}$ total body clearance (CLtot) (Tanaka et al., 1993; Yamamura et al., 1995). Another pharmacokinetic study in rats with D-Gal N induced hepatic disease didn’t show significant change in bioavailability of glycyrrhizin (Wang et al., 1996).

Use of licorice extract for peptic ulcer was reported by Revers in 1946. Studies have been conducted extensively to investigate the effect of glycyrrhizin alone, or in combination with other drugs against chronic hepatitis (Takahara et al., 1994; Arase et al., 1997; Lau et al., 2000; Tandon et al., 2001), and subacute hepatitis (caused mainly by HBV and HEV). Duration of illness and other fatal complications of subacute liver failure due to HEV are also reduced by intravenous glycyrrhizin therapy along with marked decline in elevated bilirubin concentration (Tandon et al., 2002). One of the popular preparations containing glycyrrhizin, L-cysteine and glycine that have been used in Japan for more than six decades is with the trade name of “Stronger Neo-Minophagen C” (SNMC). Initially the preparation was used as an anti-inflammatory and antidote to toxic substances. Later on, the medication was used intravenously for chronic hepatitis, plummeting serum AST (GOT) and ALT (GPT) levels in patients. A double-blind clinical trial of SNMC for treatment of chronic hepatitis was carried out by Suzuki and coworkers and observed significant decline in plasma transaminase activity and improvement of the liver cells in histological samples from the SNMC treated group (Suzuki et al., 1977). Intravenously administered glycyrrhizin is rapidly eliminated from sera, and is transformed to glycyrrhetinic monoglucuronide by means of hepatic β-glucuronidase. The intravenous administration of SNMC also led to significant decline of elevated AST and ALT levels in hepatitis patients. Significant suppression of the release of AST from hepatocytes was also found in isolated rat hepatocytes by glycyrrhizin and glycyrrhetinic acid incubated with anti-liver cell membrane.
antibody (Shiki et al., 1992; Shibata, 2000). Yoshikawa et al. (1997) using an antigen-specific murine CD4+ T hybridoma cell line, showed that glycyrrhizin restrains immune-mediated cytotoxicity against hepatocytes, and thus explaining the reduction of AST and ALT elevated plasma levels. These were the results of apoptosis of hepatocytes resulting from liver injury (Hiramatsu et al., 1994; Mita et al., 1994). Anti-Fas antibody-induced elevation of ALT in mice was counteracted by glycyrrhizin and it was hypothesized that ALT decrease in the chronic hepatitis C virus (HCV) patients treated with SNMC might be due to the inhibition of Fas-mediated hepatic injury. The anti-inflammatory effect of SNMC is believed to be mediated by its membrane protecting activity and it is associated with a lower transaminase level in chronic hepatitis patients (Watari, 1973; Utsumi, 1984). Glycyrrhizin acid inhibits cisplatin efflux from the cells and reverses cisplatin resistance in HCC cell (Wakamatsu et al., 2007). The glycyrrhizin acid effect is associated with reduced immunosuppression, cell cycle arrest, induction of autophagy and apoptosis of the HCC cells (Satomi et al., 2005). The mechanism of action of glycyrrhizin acid is via its binding to glycyrrhizin acid membrane receptors on the hepatocytes and glycyrrhetinic acid-modified novel drug delivery system for HCC was consequently developed based on the promising activity pattern of this molecule (Cai et al., 2016). Several clinical trials were also performed on SNMC to see the effect of glycyrrhizin in hepatitis and hepatocarcinogenesis (Suzuki, 1983; Hino et al., 1994; Arase et al., 1997; van Rossum et al., 1999; Ikeda et al., 2006; Veldt et al., 2006). These trials revealed the effectiveness of SNMC in the prevention of liver carcinogenesis and the effect of glycyrrhizin in decreasing the HCC, improvement of plasma transaminase activity and effect on chronic HCV infected patients with non response toward interferon. Further, glycyrrhizin therapy exhibited normalization of ALAT levels and showed less incidence of HCC.

Licorice also possesses preventive role on the development of hepatocellular carcinoma (HCC) in HCV-associated chronic hepatitis patients (Arase et al., 1997; Miyakawa and Iino, 2001). Patients with long-term abnormal serum levels of α-fetoprotein (AFP) after transfusion have high probability of HCC and histological aggravation (Ikeda et al., 1993). They could benefit using licorice to maintain normal liver function.

Based on their biological activity and efficiency in the cure of some hepatic diseases, including HCC, there is increasing interest toward the use of herbs and natural products, in the treatment and prevention of these disorders. The reviewed plants are widely used in hepatic disorders treatment and their biologically active components have been extensively studied. However, more investigations are required in order to clarify their specificity and improve their efficiency by revealing their molecular targets and mechanism of action. Further clinical studies should confirm their ability to cure jaundice and standardize their medical inference.

**CONCLUSION**

In this review we discussed in details some of the most important plants used for the treatment of jaundice. The remarkable potential of medicinal plants used in the context of gastrointestinal disorders is already well known and their utilization is quite common in ethnomedicine, however, the experimental verifications are limited. Some of the salient features are the beneficial effects in context of jaundice seen on the serum enzymes particularly in the AST, SGOT, SGPT and total bilirubin clearance. Growing number of clinical studies reveal the importance of particular plant species and their active compounds, which serve as basis for further drug development.

More studies are required in order to improve the efficiency and specificity of jaundice treatment based on ethnopharmacological knowledge and to standardize the clinical procedures. The broad spectrum of biologically active compounds could allow additional applications beyond jaundice cure, like gastrointestinal disorders, blood pressure and so on. The high efficiency and low number of side effects by using plant constituents indicates the ethnopharmacological approach of jaundice treatment as a high priority for future research.

**AUTHOR CONTRIBUTIONS**

DT, AM, EP, ZM, YL, and AA have written the first draft of the manuscript. AS, SN, LH, and JH revised and improved the first draft. All authors have seen and agreed on the finally submitted version of the manuscript.

**ACKNOWLEDGMENTS**

AA acknowledges the support by the Polish KNOW (Leading National Research Centre) Scientific Consortium “Healthy Animal—Safe Food,” decision of Ministry of Science and Higher Education No. 05-1/KNOW2/2015. AM acknowledges the support by UEFISCDI, Romania, project no. PNII-RUTE-2014-4-1247 and ZM was supported by a postdoctoral research fellowship from the Universiti Sains Malaysia Research University Individual (RUI) grant (ref. no. 1001/PPSP/812151).

**REFERENCES**

Agarwal, K., Dhir, H., Sharma, A., and Talukder, G. (1992). The efficacy of two species of *Phyllanthus* in countering nickel clastogenicity. *Fitoterapia* 63, 49–54.

Akbarsha, M. A., and Murugaian, P. (2000). Aspects of the male reproductive toxicity/male antifertility property of andrographolide in albino rats: effect on the testis and the cauda epididymidal spermatozoa. *Phytother. Res.* 14, 432–435. doi: 10.1002/1099-1573(200009)14:6<432::AID-PTR622>3.0.CO;2-I

Alcaraz, M. J., and Jiménez, M. J. (1988). Flavonoids as anti-inflammatory agents. *Fitoterapia* 59, 25–38.

Al-Qarawi, A. A., Abdel-Rahman, H. A., and El-Mougy, S. A. (2001). Hepatoprotective activity of licorice in rat liver injury models. *J. Herbs Spices Med. Plants* 8, 7–14. doi: 10.1300/J044v08n01_02
Andan, K. K., Singh, B., Saxena, A. K., Chandan, B. K., and Gupta, V. N. (1994). Hepatoprotective studies of a fraction from the fruits of *Terminalia belerica* Roxb. On experimental liver injury in rodents. *Phytother. Res.* 8, 287–292. doi: 10.1002/ptr.2650080507

Angulo, F., Patel, T., Jorgensen, R. A., Therneau, T. M., and Lindor, K. D. (2000). Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. *Hepatology* 32, 897–900. doi: 10.1053/hep.2000.18663

Arase, Y., Ikeda, K., Murashima, N., Chayama, K., Tsubota, A., Koida, I., et al. (1997). The long term efficacy of glycyrrhizin in chronic hepatitis C patients. *Cancer* 79, 1494–1500. doi: 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B

Ariserelatne, S. N., Gunatilaka, A. A. L., and Panabokke, R. G. (1985). Studies on medicinal plants of Sri Lanka. Part 14: toxicity of some traditional medicinal herbs. *J. Ethnopharmacol.* 13, 323–335. doi: 10.1016/0378-8741(85)90078-9

Ast, M. N., and Hosseinzadeh, H. (2008). Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. *Phytother. Res.* 22, 709–724. doi: 10.1002/ptr.2362

Bachmann, T. L., Ghia, F., and Torssell, K. J. C. (1978). Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase. *Experientia* 34, 1054–1055. doi: 10.1007/BF01915343

Blumenthal, M., Goldberg, A., and Brinkmann, J. (2000). *The Complete German Commission E Monographs Cd-Rom*. Austin, TX: American Botanical Council.

Bunout, D., Hirsch, S., Petermann, M., De La Maza, M. P., Silva, G., Kelly, M., et al. (1992). Controlled study of the effect of silymarin on alcoholic liver disease. *Rev. Med. Chil* 120, 1370–1375.

Cai, Y., Xu, Y., Chan, H. F., Fang, X., He, C., and Chen, M. (2016). Glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy. *Mol. Pharm.* 13, 699–709. doi: 10.1021/acs.molpharmaceut.5b00677

Calbrese, C., Berman, S. H., Babish, J. G., Ma, X., Shinto, L., Dorr, M., et al. (2000). A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytother. Res.* 14, 333–338. doi: 10.1002/(SICI)1099-1573(20000814):14<333::AID-PTR846>3.0.CO;2-D

Calixto, J. B., Santos, A. R. S., Filho, V. C., and Yunes, R. A. (1998). A review of the plants of the genus *Phyllanthus*: and therapeutic potential. *Med. Res. Rev.* 18, 225–258. doi: 10.1002/(SICI)1099-1188(19980718)8:4<225::AID-MEDR2>3.0.CO;2-X

Campos, A. H., and Schor, N. (1999). *Phyllanthus niruri* inhibits calcium oxalate endocytosis by renal tubular cells: its role in urolithiasis. *Nephron* 81, 393–397. doi: 10.1159/000045322

Chander, R., Srivastava, V., Tandon And, J. S., and Kapoor, N. K. (1995). Antihelminthic activity of diterpenes of *Andrographis paniculata* (Kal-Megh) against *Plasmodium berghei*-induced hepatic damage in *Mastomys natalensis*. *Int. J. Pharm. BioSci.* 33, 135–138. doi: 10.3109/1388029590955213

Chatterjee, A., and Pakrashi, S. C. (1991). *The Treatise on Indian Medicinal Plants*; [with] Supplement. *O. J. Council of Scientific & Industrial Research.

Chung, H., and Hong, S. (1996). *Screening of Indian plants for biological activity: Part 1*. New Delhi: Publications and Information Directorate, CSIR, 172.

Cui, Y. B., Xu, J., Wang, X. C., Wang, G., and Zhang, Y. (1993). The antiinflammatory activity of licorice on the renin-angiotensin aldosterone axis in normal subjects. *Br. Med. J.* 306, 1059–1060. doi: 10.1136/bmj.306.6889.1059

Evans, W. C. (2009). *Taste and Evans’ Pharmacognosy*. Amesterdam: Elsevier.

Fahimi, J., Dehghani, M., and Dehghani, M. (2009). The antiinflammatory activity of glycyrrhetic acid and derivatives. *J. Pharm. Pharmacol.* 61, 1231–1236. doi: 10.1111/j.2042-7158.2009.tb03928.x

Finney, R. S., and Somers, G. F. (1958). The antiinflammatory activity of Glycyrrhiza sp. and its bioactive compounds. *Eur. J. Drug Metab. Pharmacokinet.* 15, 333–338. doi: 10.1007/BF03190223

Beret, A., Anton, R., and Stoclet, J. C. (1978). Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase. *Experientia* 34, 1054–1055. doi: 10.1007/BF01915343

Blumenthal, M., Goldberg, A., and Brinkmann, J. (2000). *Herbal Medicine, Expanded Edition & Monographs Cd-Rom*. Austin, TX: American Botanical Council.

Bunout, D., Hirsch, S., Petermann, M., De La Maza, M. P., Silva, G., Kelly, M., et al. (1992). Controlled study of the effect of silymarin on alcoholic liver disease. *Rev. Med. Chil* 120, 1370–1375.

Cai, Y., Xu, Y., Chan, H. F., Fang, X., He, C., and Chen, M. (2016). Glycyrrhetinic acid mediated drug delivery carriers for hepatocellular carcinoma therapy. *Mol. Pharm.* 13, 699–709. doi: 10.1021/acs.molpharmaceut.5b00677

Calbrese, C., Berman, S. H., Babish, J. G., Ma, X., Shinto, L., Dorr, M., et al. (2000). A phase I trial of andrographolide in HIV positive patients and normal volunteers. *Phytother. Res.* 14, 333–338. doi: 10.1002/(SICI)1099-1573(20000814):14<333::AID-PTR846>3.0.CO;2-D

Calixto, J. B., Santos, A. R. S., Filho, V. C., and Yunes, R. A. (1998). A review of the plants of the genus *Phyllanthus*: and therapeutic potential. *Med. Res. Rev.* 18, 225–258. doi: 10.1002/(SICI)1099-1188(19980718)8:4<225::AID-MEDR2>3.0.CO;2-X

Campos, A. H., and Schor, N. (1999). *Phyllanthus niruri* inhibits calcium oxalate endocytosis by renal tubular cells: its role in urolithiasis. *Nephron* 81, 393–397. doi: 10.1159/000045322

Chander, R., Srivastava, V., Tandon And, J. S., and Kapoor, N. K. (1995). Antihelminthic activity of diterpenes of *Andrographis paniculata* (Kal-Megh) against *Plasmodium berghei*-induced hepatic damage in *Mastomys natalensis*. *Int. J. Pharm. BioSci.* 33, 135–138. doi: 10.3109/1388029590955213

Chatterjee, A., and Pakrashi, S. C. (1991). *The Treatise on Indian Medicinal Plants*, Vol. 1. New Delhi: Publications and Information Directorate, CSIR, 172.

Choi, M.-K., Kim, H.-G., Han, J.-M., Lee, J.-S., Lee, J. S., Chung, S. H., et al. (2015). Hepatoprotective effect of *Terminalia chebula* against t-BHP-induced acute liver injury in C57BL/6 mice. *Evid. Based Complement. Alternat. Med.* 2015:517350. doi: 10.1155/2015/517350

Chopra, R. N., Nayar, S. L., Chopra, I. C., Asolkar, L. V., Kakkar, K. K., and Chakre, O. J. (1956). *Glossary of Indian medicinal plants*; [with] Supplement. New Delhi: Council of Scientific & Industrial Research.

Choudhury, B. R., and Poddar, M. K. (1984). Andrographolide and kalmegh (*Andrographis paniculata*) extract: in vivo and in vitro effect on hepatic lipid peroxidation. *Methods Find. Exp. Clin. Pharmacol.* 6, 481–485.
Li, Z., Li, Q., Jiang, X., Zhang, K., and Guan, R. (2014). Isolation and preparation of gallic acid from *Terminalia chebula* Retz. with high-speed counter-current chromatography. *Pe Pe* 32, 1404–1408.

Lin, C. N., and Tome, W. P. (1988). Antifibrotic principles of *Sambucus* formosana. *Planta Med.* 54, 223–224. doi: 10.1055/s-2006-962410

Lin, G., Jinane, J. P., and Cheng, T.-Y. (1999). The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retorsine-induced hepatotoxicity in rats. *Toxicol* 37, 1259–1270. doi: 10.1007/s00414-0019(98)00263-3

Lindahl, M., and Tagesson, C. (1993). Selective inhibition of group II phospholipase A2 by quercetin. *Inflammation* 17, 573–582. doi: 10.1007/BF00914195

Loguercio, C., and Festi, D. (2011). Silybin and the liver: from basic research to clinical practice. *World J. Gastroenterol.* 17, 2288–2301. doi: 10.3748/wjg.v17.i18.2288

Luper, S. (1998). A review of plants used in the treatment of liver disease: part 1. *Altern. Med. Rev.* 3, 410–421.

Mabberley, D. J. (2008). *Mabberley’s Plant-book: A Portable Dictionary of Plants, Their Classification and Uses*. Cambridge: Cambridge University Press.

Mao, X., Wu, L.-F., Guo, H.-L., Chen, W.-J., Cui, Y.-P., Qi, Q., et al. (2014). Isolation and preparation of silymarin from *Silybum marianum*. *Fitoterapia* 66, 3–42.

Miadonna, A., Tedeschi, A., Leggieri, E., and Zanussi, C. (1995). Selective inhibition of group II phospholipase A2 by quercetin. *Inflammation* 17, 573–582. doi: 10.1007/BF00914195

Mita, E., Hayashi, N., Iio, S., Takehara, T., Hijioka, T., Kasahara, A., et al. (1994). A comparison of the antihepatotoxic activity between glycyrrhizin and silymarin. *Br. J. Clin. Pharmacol.* 37, 1199–1206. doi: 10.1111/j.1365-2123.1994.tb02541.x

Mhaskar, K. S., Blatter, E., and Caius, J. F. (2000). *Andrographolide analogues as novel cytotoxic agents*. Cambridge, MA: MIT Press, 149–151.

Mii, F. G., and Oyedeji, B. M. (1997). *Analysis of some herbal plants from Yucatan species,* *Phyllanthus niruri* and its constituent, *Phyllanthus acuminatus*. *Afr. J. Biomed. Res.* 4, 131–133.

Moli, A., and Saha, S. (1999). *Tripteris hemsleyana*—a potent antihepatotoxic agent. *Phytother. Res.* 13, 603–606. doi: 10.1002/ptr.4720130509

Mital, M. S., and Sood, R. S. (2003). *Bilberries* are an effective functional food. *Indian J. Med. Sci.* 57, 387.

Morazzoni, P., and Bombardelli, E. (1995). *Silybum marianum*—its active principles and traditional uses. *Ger. Z. Naturforsch.* 50c, 3–14. doi: 10.1515/GZNF.1995.50c.3

Naik, A. D., and Juvekar, A. R. (2003). Effects of alkaloidal extract of *Niruriside*, a new HIV REV/RRE binding inhibitor from *Andrographis paniculata* on HIV replication. *Indian J. Med. Sci.* 57, 387.

Oda, P. (2000). *The Complete Guide Medicinal Herbal*. London: Dorling Kindersley.
